Title |
A Comprehensive and Observational Myeloproliferative
Neoplasms (MPN) Registry in the Province of Quebec |
Protocole ID |
Registre des NMP (CINC424BCA04T) |
ClinicalTrials.gov ID |
|
Cancer Type(s) |
MPN: Vaquez, Essential Thrombocytemia, Myeloid Metaplasia |
Phase |
Other |
Stage |
|
Study Type |
|
Drug |
|
Institution |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
5415 boul. de l'Assomption, Montréal, QC, H1T2M4
|
City |
Montréal |
Principal Investigator |
Dr. Lambert Busque
|
Coordinator |
Michel-Olivier Gratton
514-252-3400 poste 2397
|
Status |
Recruiting |
Activation Date |
|
Eligibility Criteria |
All patients who meet the following inclusion criteria may be enrolled in the MPN Registry:
- Have a diagnosis of PV, ET, or MF as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms [7];
- Are 18 years of age or older;
- Are able to give written, informed consent (or have a legal representative who can give written, informed consent when applicable).
|
Exclusion Criteria |
Patients who meet any of the following criteria will be excluded from participation:
- Life expectancy of less than 3 months for a condition not related to MPN;
- Patients suffering of CML.
|
|
|